Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Mobley Clinical Research Center
mi
from
Houston, TX
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Mobley Clinical Research Center
mi
from
Houston, TX
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Fletcher Allen Health Care
mi
from
Burlington, VT
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Fletcher Allen Health Care
mi
from
Burlington, VT
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Urology of Virginia
mi
from
Norfolk, VA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Urology of Virginia
mi
from
Norfolk, VA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Virginal Urology
mi
from
Richmond, VA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Virginal Urology
mi
from
Richmond, VA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Seattle Urology Research Center
mi
from
Seattle, WA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Seattle Urology Research Center
mi
from
Seattle, WA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Roger D. Fincher, PS
mi
from
Spokane, WA
A Study of Degarelix in Patients With Prostate Cancer
A Randomized, Controlled, Open-Label Study Investigating the Safety and Efficacy of Degarelix Given Intermittently vs Continuous Androgen Deprivation Therapy With Lupron or Degarelix in Patients With Prostate Cancer With Prior Treatment Failure After Localized Treatment
Status: Archived
Updated: 1/1/1970
Roger D. Fincher, PS
mi
from
Spokane, WA
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer
Status: Archived
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
Phase I/II Study of Lenalidomide (RevlimidTM ) and GM-CSF in Androgen Independent Prostate Cancer
Status: Archived
Updated: 1/1/1970
Taussig Cancer Center, Cleveland Clinic Foundation
mi
from
Cleveland, OH
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.
Status: Archived
Illinois Cancer Care
mi
from
Peoria, IL
Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Refractory to Total Androgen Blockade
A Study of Pazopanib as Second Line Therapy in Patients With Metastatic Prostate Cancer Who Have Received Prior Therapy With an LHRH Agonist.
Status: Archived
Updated: 1/1/1970
Illinois Cancer Care
mi
from
Peoria, IL
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Status: Archived
Oregon Health and Science University
mi
from
Portland, OR
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Exercising Together: An Intervention for Prostate Cancer Survivors and Spouses
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
mi
from
Portland, OR
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
San Bernandino Urology
mi
from
San Bernardino, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
San Bernandino Urology
mi
from
San Bernardino, CA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Comprehensive Cancer Care Centers of Nevada
mi
from
Henderson, NV
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Comprehensive Cancer Care Centers of Nevada
mi
from
Henderson, NV
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Roswell Park Cancer Center Institute
mi
from
Buffalo, NY
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Greenville Hospital System Univeristy Medical Center
mi
from
Greenville, SC
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Greenville Hospital System Univeristy Medical Center
mi
from
Greenville, SC
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
University of Washington; UW Medical Center
mi
from
Seattle, WA
ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer
ARMOR1: Phase 1/2, Open Label, Dose Escalation, Selected Dose Comparison Trial of TOK-001 for the Treatment of Chemotherapy Naive Castration Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Washington; UW Medical Center
mi
from
Seattle, WA
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors
Status: Archived
Pfizer Investigational Site
mi
from
Duluth, MN
Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
Phase 1 Safety And Tolerability Study Of Figitumumab Combined With Pegvisomant In Patients With Advanced Solid Tumors
Status: Archived
Updated: 1/1/1970
Pfizer Investigational Site
mi
from
Duluth, MN
Genetic Investigation of Solid Tumors Cohort
Genetic Investigation of Solid Tumors Cohort
Status: Archived
Scripps HealthCare
mi
from
LaJolla, CA
Genetic Investigation of Solid Tumors Cohort
Genetic Investigation of Solid Tumors Cohort
Status: Archived
Updated: 1/1/1970
Scripps HealthCare
mi
from
LaJolla, CA
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
University of Chicago
mi
from
Chicago, IL
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Johns Hopkins University
mi
from
Baltimore, MD
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
Johns Hopkins University
mi
from
Baltimore, MD
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Wayne State University
mi
from
Detroit, MI
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
Wayne State University
mi
from
Detroit, MI
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
University of Washington
mi
from
Seattle, WA
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Washington
mi
from
Seattle, WA
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
University of Wisconsin-Madison
mi
from
Madison, WI
A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
A Phase II, Open-Label, Single-Arm Study Evaluating the Safety, Efficacy and Pharmacokinetics of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Had Prior Chemotherapy
Status: Archived
Updated: 1/1/1970
University of Wisconsin-Madison
mi
from
Madison, WI
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Chevy Chase, MD
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Clinical Trial Facility
mi
from
Detroit, MI
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Detroit, MI
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Clinical Trial Facility
mi
from
Albany, NY
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Albany, NY
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Clinical Trial Facility
mi
from
Medford, OR
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Medford, OR
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer
A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Failed Up to Two Non-hormonal Systemic Therapies
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
A Randomized Phase-II Pilot Trial of Docetaxel and Prednisone Versus Radiation Therapy Plus Docetaxel and Prednisone in Patients With Nonmetastatic and Oligometastatic Castrate Resistant Prostate Cancer
Status: Archived
Northwestern University
mi
from
Chicago, IL
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
A Randomized Phase-II Pilot Trial of Docetaxel and Prednisone Versus Radiation Therapy Plus Docetaxel and Prednisone in Patients With Nonmetastatic and Oligometastatic Castrate Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Northwestern University
mi
from
Chicago, IL
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
A Randomized Phase-II Pilot Trial of Docetaxel and Prednisone Versus Radiation Therapy Plus Docetaxel and Prednisone in Patients With Nonmetastatic and Oligometastatic Castrate Resistant Prostate Cancer
Status: Archived
Hematology and Oncology Associates
mi
from
Chicago, IL
Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer
A Randomized Phase-II Pilot Trial of Docetaxel and Prednisone Versus Radiation Therapy Plus Docetaxel and Prednisone in Patients With Nonmetastatic and Oligometastatic Castrate Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Hematology and Oncology Associates
mi
from
Chicago, IL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Dana-Farber / Harvard Cancer Center
mi
from
Boston, MA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Miami, FL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Miami, FL
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Alexandria, LA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Alexandria, LA
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Clinical Research Facility
mi
from
Fort Worth, TX
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
A Phase 3b, Randomized, Double-blind, Placebo-controlled Parallel-design Study to Evaluate the Efficacy and Safety of Tadalafil Co-administered With Finasteride for 6 Months in Men With Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
Status: Archived
Updated: 1/1/1970
Clinical Research Facility
mi
from
Fort Worth, TX
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.
Status: Archived
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
Phase I Clinical Trial of Temsirolimus and Vinorelbine in Advanced Solid Tumors.
Status: Archived
Updated: 1/1/1970
Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
Phase I Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
Status: Archived
Memorial Sloan Kettering
mi
from
New York City, NY
Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
Phase I Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
Status: Archived
Updated: 1/1/1970
Memorial Sloan Kettering
mi
from
New York City, NY
Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy
Status: Archived
Johns Hopkins Hosp
mi
from
Baltimore, MD
Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy
Status: Archived
Updated: 1/1/1970
Johns Hopkins Hosp
mi
from
Baltimore, MD
Laser Based Focal Ablation of Low Grade Prostate Cancer
A Pilot Study to Evaluate Magnetic Resonance Thermal Image-guided Laser-Induced Interstitial Thermal Therapy for Focal Ablation of Prostate Cancer
Status: Archived
University of Chicago
mi
from
Chicago, IL
Laser Based Focal Ablation of Low Grade Prostate Cancer
A Pilot Study to Evaluate Magnetic Resonance Thermal Image-guided Laser-Induced Interstitial Thermal Therapy for Focal Ablation of Prostate Cancer
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer
Status: Archived
Mount Sinai Hospital
mi
from
New York, NY
Neoadjuvant Study of In-situ REIC/Dkk-3 in Prostate Cancer
A Phase I Neoadjuvant Study of In-situ REIC/Dkk-3 Therapy Followed By Prostatectomy in Patients With High Risk Localized Prostate Cancer
Status: Archived
Updated: 1/1/1970
Mount Sinai Hospital
mi
from
New York, NY
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy
Status: Archived
Puget Sound VA Medical Center
mi
from
Seattle, WA
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Phase III Randomized, Double-Blind, Placebo Controlled, Multicenter Efficacy and Safety Study of Toremifene Citrate 80 mg for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer on Androgen Deprivation Therapy
Status: Archived
Updated: 1/1/1970
Puget Sound VA Medical Center
mi
from
Seattle, WA
Metformin in Castration-Resistant Prostate Cancer
Prospective Study of Metformin in Castration-Resistant Prostate Cancer
Status: Archived
Massachusetts General Hospital
mi
from
Boston, MA
Metformin in Castration-Resistant Prostate Cancer
Prospective Study of Metformin in Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Massachusetts General Hospital
mi
from
Boston, MA
Metformin in Castration-Resistant Prostate Cancer
Prospective Study of Metformin in Castration-Resistant Prostate Cancer
Status: Archived
Dana-Farber Cancer Institute
mi
from
Boston, MA
Metformin in Castration-Resistant Prostate Cancer
Prospective Study of Metformin in Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Dana-Farber Cancer Institute
mi
from
Boston, MA
Metformin in Castration-Resistant Prostate Cancer
Prospective Study of Metformin in Castration-Resistant Prostate Cancer
Status: Archived
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Metformin in Castration-Resistant Prostate Cancer
Prospective Study of Metformin in Castration-Resistant Prostate Cancer
Status: Archived
Updated: 1/1/1970
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Status: Archived
City of Hope Medical Canter
mi
from
Duarte, CA
Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
Status: Archived
Updated: 1/1/1970
City of Hope Medical Canter
mi
from
Duarte, CA
The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer
The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer
Status: Archived
Oregon Health and Science University
mi
from
Portland, OR
The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer
The Effects of Sulforaphane in Patients With Biochemical Recurrence of Prostate Cancer
Status: Archived
Updated: 1/1/1970
Oregon Health and Science University
mi
from
Portland, OR
Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1
Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1
Status: Archived
Palo Alto Medical Foundation Research Institute
mi
from
Palo Alto, CA
Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1
Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1
Status: Archived
Updated: 1/1/1970
Palo Alto Medical Foundation Research Institute
mi
from
Palo Alto, CA
Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1
Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1
Status: Archived
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
Decision Support Interventions (DESI) for Prostate Cancer Screening - Study 1
Acceleration Adoption of Comparative Effectiveness Research Results With Patient Decision Support Intervention and Treatment (DESI)- Study 1
Status: Archived
Updated: 1/1/1970
University of North Carolina Hospital at Chapel Hill
mi
from
Chapel Hill, NC
A Degarelix Trial in Patients With Prostate Cancer
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
Status: Archived
Urology Associates of Central CA
mi
from
Fresno, CA
A Degarelix Trial in Patients With Prostate Cancer
An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Deprivation Therapy
Status: Archived
Updated: 1/1/1970
Urology Associates of Central CA
mi
from
Fresno, CA